載入...
CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
Maraviroc (MVC) is the first licensed antiretroviral therapeutic agent to target a host cell surface molecule, and successful HIV-1 entry blockade by this C-C chemokine receptor type 5 (CCR5)-antagonist potentiates immunomodulation. We hypothesized that MVC intensification impacts immunization respo...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
ScholarOne
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3510292/ https://ncbi.nlm.nih.gov/pubmed/22875102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2119/molmed.2012.00206 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|